May 07, 2025

Dr. Vinay Prasad Shakes Up FDA Leadership

The FDA has appointed Vinay Prasad as its new vaccine chief, shaking up biotech stocks and signaling potential shifts in drug approvals.

Reuters

May 07, 2025

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings

Two pivotal phase III trials presented at the 2024 ASH Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia, offering potentiall...

The ASCO Post

May 07, 2025

Is Clonal Cytopenia of Undetermined Significance Distinct From Lower-Risk Myelodysplastic Syndrome?

High-risk patients with clonal cytopenia of undetermined significance have very similar characteristics and outcomes as patients with lower-risk myelodysplastic syndrome (MDS), which can be informativ...

The ASCO Post

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 02, 2025

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia

Two experts discuss strategies and clinical considerations when treating patients with AML who are ineligible for intensive chemotherapy as well as those who are eligible for intensive chemotherapy.

The ASCO Post

May 01, 2025

Ocular Surface Disease Treatments in the Pipeline

Potential treatments address inflammation and tear production, offer alternative mechanisms of action, or address a subset of dry eye.

Ophthalmology Management

May 01, 2025

Explore the latest in retinal disorder research and treatment at the global Retina World Congress, where leading experts share best practices and advancements.

Retinal Physician

May 01, 2025

Discover the latest advancements in the diagnosis and treatment of retinal diseases at the premier Retina World Congress.

Retinal Physician

April 30, 2025

FDA Approves FcRn Blocker for Broad gMG Use

The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.

Conexiant